Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1

Status

Active not recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4Sarcoma 2

Conditions

Prostatic Neoplasms 12Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 5Breast Neoplasms 5Lung Neoplasms 4Glioblastoma 4Neoplasms 3Myelodysplastic Syndromes 3Squamous Cell Carcinoma of Head and Neck 2Mycosis Fungoides 2Mouth Neoplasms 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Liver Neoplasms 2Leukemia, Myeloid, Acute 2Gliosarcoma 2Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Thrombosis 1Radiation Injuries 1Prostatic Neoplasms, Castration-Resistant 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Neurofibromatosis 1 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Mesothelioma, Malignant 1Meningioma 1

Interventions

Temozolomide 405Radiotherapy 202Bevacizumab 157Radiation 80Magnetic Resonance Spectroscopy 77Lomustine 49Surgical Procedures, Operative 45Carmustine 41pembrolizumab 40Irinotecan 38Nivolumab 32Specimen Handling 28Carboplatin 27Radiosurgery 24Erlotinib Hydrochloride 24Drug Therapy 23Chemotherapy, Adjuvant 23Radiotherapy, Intensity-Modulated 22Cyclophosphamide 20Aminolevulinic Acid 20O(6)-benzylguanine 17sargramostim 16Radiotherapy, Conformal 15Blood Specimen Collection 15temsirolimus 14Granulocyte-Macrophage Colony-Stimulating Factor 14Everolimus 14Vorinostat 13Sorafenib 13Ipilimumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Glioblastoma × Photons × Clear all
NCT05095376 2026-05-19

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

NRG Oncology

Phase 3 Active not recruiting
265 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT07422363 2026-05-13

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
30 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT02179086 2026-01-14

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2 Active not recruiting
606 enrolled
CNS

Glioblastoma

NCT03587038 2025-12-10

OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma

University of Oklahoma

Phase 1 Active not recruiting
27 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡